UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2109-10
Program Prior Authorization/Medical Necessity
Medication Xyntha® (antihemophilic factor [recombinant])
P&T Approval Date 10/2016, 12/2016, 4/2018, 3/2019, 10/2019, 9/2020, 9/2021, 9/2022,
9/2023, 9/2024
Effective Date 12/1/2024
1. Background:
Xyntha® (antihemophilic factor [recombinant]) is a recombinant antihemophilic factor indicated
in adults and children with hemophilia A (congenital Factor VIII deficiency) for:1
On-demand treatment and control of bleeding episodes
o
Perioperative management
o
Routine prophylaxis to reduce the frequency of bleeding episodes
o
Xyntha is not indicated for the treatment of von Willebrand’s disease.
2. Coverage Criteriaa:
A. Initial Authorization
1. Xyntha will be approved based on both of the following criteria:1-6
a. Diagnosis of hemophilia A
-AND-
b. One of the following:
(1) Submission of documentation showing failure to meet clinical goals (e.g.,
continuation of spontaneous bleeds, inability to achieve appropriate trough
level) after a trial of three of the following recombinant factor products:
(a) Advate
(b) Kogenate FS
(c) Kovaltry
(d) NovoEight
(e) Nuwiq
(f) Recombinate
-OR-
(2) Submission of documentation showing history of hypersensitivity to three of
the following recombinant factor products:
(a) Advate
© 2024 UnitedHealthcare Services, Inc.
1
(b) Kogenate FS
(c) Kovaltry
(d) NovoEight
(e) Nuwiq
(f) Recombinate
-OR-
(3) Prescriber attestation that patient would preferentially benefit from Xyntha
based on one of the following:
(a) Patient is at high risk for the development of inhibitors (e.g., family history
of inhibitors and success with product, current treatment less than 50 days,
high risk genetic mutation, history of initial intensive therapy greater than 5
days)
(b) Patient has developed inhibitors
(c) Patient has undergone immune tolerance induction/immune tolerance
therapy
Authorization of therapy will be issued for 12 months.
B. Reauthorization
1. Xyntha will be approved based on the following criterion:
a. Documentation of positive clinical response to Xyntha therapy.
Authorization of therapy will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
4. References:
1. Xyntha® [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc., July 2022.
2. ter Avest PC, Fischer K, Mancuso ME, et al. Risk stratification for inhibitor development at
first treatment for severe hemophilia A: a tool for clinical practice. J Thromb Haemost.
2008; 6: 2048–54.
3. Hoots WK, Shapiro AD. Hemophilia A and B: Routine management including prophylaxis
. In: UpToDate, Waltham, MA, 2024.
4. Hoots WK, Shapiro AD. Inhibitors in hemophilia: Mechanisms, prevalence, diagnosis, and
eradication. In: UpToDate, Waltham, MA, 2024.
© 2024 UnitedHealthcare Services, Inc.
2
5. MASAC Recommendations Concerning Products Licensed for the Treatment of
Hemophilia and Selected Disorders of the Coagulation System . MASAC Document #284,
April 11, 2024.
6. MASAC Recommendation on SIPPET (Survey of Inhibitors in Plasma-Product-Exposed
Toddlers): Results and Recommendations for Treatment Products for Previously Untreated
Patients with Hemophilia A. MASAC Document #243, June 28 2016.
Program Prior Authorization/Medical Necessity - Xyntha
Change Control
10/2016 New program.
12/2016 Updated criteria to allow for use in routine prophylaxis in addition to
acute treatment and perioperative management.
4/2018 Annual review with no change to clinical intent. Revised formatting.
Updated state mandate verbiage. Updated references.
3/2019 Annual review with no changes to coverage criteria. Updated reference.
10/2019 Annual review with no changes to coverage criteria.
9/2020 Updated background to include new indication for routine prophylaxis.
Modified program updating preferred agents, adding Advate and
Recombinate. Updated reference.
9/2021 Annual review with no changes to coverage criteria. Updated
background.
9/2022 Annual review with no changes to coverage criteria. Updated
references.
9/2023 Annual review. Modified physician attestation to prescriber attestation.
Updated references.
9/2024 Annual review. Revised outline of coverage criteria without change to
clinical intent. Updated references.
© 2024 UnitedHealthcare Services, Inc.
3